NR3C2 and muscular dystrophy: These data further support that MR antagonist treatment is protective for fragile myofibers, as we have shown in muscular dystrophy models (Rafael-Fortney et al., 2011; Lowe et al., 2016; Chadwick et al., 2017a; Hauck et al., 2019).